摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-[5-(1-tert-butoxycarbonylamino-1-methylethyl)-pyridin-2-yl]-1-(tetrahydropyran-2-yl)-4-vinyl-1H-indazole | 850363-08-5

中文名称
——
中文别名
——
英文名称
5-[5-(1-tert-butoxycarbonylamino-1-methylethyl)-pyridin-2-yl]-1-(tetrahydropyran-2-yl)-4-vinyl-1H-indazole
英文别名
tert-butyl N-[2-[6-[4-ethenyl-1-(oxan-2-yl)indazol-5-yl]pyridin-3-yl]propan-2-yl]carbamate
5-[5-(1-tert-butoxycarbonylamino-1-methylethyl)-pyridin-2-yl]-1-(tetrahydropyran-2-yl)-4-vinyl-1H-indazole化学式
CAS
850363-08-5
化学式
C27H34N4O3
mdl
——
分子量
462.592
InChiKey
ZRROAJJPHQLSCC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.8
  • 重原子数:
    34
  • 可旋转键数:
    7
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.44
  • 拓扑面积:
    78.3
  • 氢给体数:
    1
  • 氢受体数:
    5

反应信息

点击查看最新优质反应信息

文献信息

  • Novel indazole derivatives
    申请人:Hagihara Masahiko
    公开号:US20070129404A1
    公开(公告)日:2007-06-07
    An object of the present invention is to create a novel indazole derivative useful as a drug and to find a novel pharmacological action of the derivative. The compound of the present invention is represented by the formula [I] and has an excellent Rho kinase inhibiting action. In the formula, a ring X is a benzene ring or a pyridine ring; R 1 and R 2 are H or alkyl; R 3 and R 4 are halogen, H, OH, alkoxy, alkenyloxy, alkynyloxy, cycloalkyloxy, cycloalkenyloxy, aryloxy, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, carboxy, hydrocarbonyl, alkylcarbonyl, etc.; and R 5 is halogen atom, H, OH, alkoxy, aryloxy, alkyl or aryl. Each group can be substituted.
    本发明的目的是创建一种新的吲唑生物作为药物,并找到该衍生物的新的药理作用。本发明的化合物由公式[I]表示,并具有出色的Rho激酶抑制作用。在公式中,环X是环或吡啶环;R1和R2是H或烷基;R3和R4是卤素,H,OH,烷基,基,炔基,环烷基,环基,芳基,烷基,基,炔基,环烷基,环基,芳基,羧基,烷基羰基等;而R5是卤素原子,H,OH,烷基,芳基,烷基或芳基。每个基团都可以被取代。
  • Methods for treating a disease in which Rho kinase is involved
    申请人:Hagihara Masahiko
    公开号:US20090264468A1
    公开(公告)日:2009-10-22
    A method for treating a disease in which Rho kinase is involved. The method is carried out by administering to a patient in need thereof a pharmaceutically effective amount of a compound of the following formula or a pharmaceutically acceptable salt thereof: , wherein the ring X is a benzene ring or a pyridine ring; R 1 and R 2 are hydrogen or alkyl or together form a cycloalkene ring; R 3 is hydrogen, substituted alkyl, unsubstituted alkenyl, carboxyl or an ester or an amide thereof, amino or a cyano; R 4 is hydrogen, hydroxyl, substituted or unsubstituted alkoxy, unsubstituted alkenyloxy, unsubstituted cycloalkyloxy, substituted or unsubstituted alkyl, unsubstituted alkenyl, unsubstituted cycloalkyl, amino, substituted or unsubstituted alkylamino, nitro, cyano or a monocyclic heterocycle; and R 5 is a halogen atom or a hydrogen atom.
  • US7563906B2
    申请人:——
    公开号:US7563906B2
    公开(公告)日:2009-07-21
  • US7855222B2
    申请人:——
    公开号:US7855222B2
    公开(公告)日:2010-12-21
  • US8232308B2
    申请人:——
    公开号:US8232308B2
    公开(公告)日:2012-07-31
查看更多